Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Relmada Therapeutics, Inc. (RLMD) had Consolidated Net Income/Loss of $-9.87M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-9.87M |
|
-- |
|
-- |
|
$10.22M |
|
$-10.22M |
|
$0.35M |
|
$-9.87M |
|
$-9.90M |
|
$-9.87M |
|
$-9.87M |
|
|
Consolidated Net Income/Loss |
$-9.87M |
$-9.90M |
|
$-10.22M |
|
$-10.22M |
|
33.19M |
|
33.19M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$21.09M |
|
-- |
|
$0.02M |
|
$21.12M |
|
$5.13M |
|
-- |
|
$0.03M |
|
$5.17M |
|
$15.95M |
|
$15.95M |
|
$15.95M |
|
33.19M |
|
| Cash Flow Statement Financials | |
$-24.47M |
|
$22.04M |
|
$-0.07M |
|
$3.86M |
|
$1.35M |
|
$-2.50M |
|
$7.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-61.86% |
|
-61.86% |
|
-46.72% |
|
-61.86% |
|
$0.48 |
|
$-0.74 |
|
$-0.74 |
|